– Takeda’s deal to buy London-listed Shire is the biggest overseas acquisition by a Japanese company.
– It’s also one of the most indebted, with the company having secured $30.9 billion in bank loans.
– Takeda shares have fallen 25 percent since it revealed interest in buying Shire — they closed up 1 percent at on Wednesday.
Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Takeda will be joining the ranks of the world’s top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company.
Industry experts are grappling with the eventual requirement to provide accurate supply-chain traceability.
Not withstanding FDA’s June 30 announcement that it was delaying enforcement of the Drug Supply Chain Security Act’s next phase by one year (November 2017 to November 2018), the global pharma industry will have invested several billion dollars in hardware and software to comply with that law and related efforts to secure the pharma supply chain around the world.
And while other countries have their own pathway toward providing traceability of pharma shipments, the US’ effort has a small problem: as written, no one knows how the law will work effectively by 2023 when all of its components are to be in place. Oops!
Click here for more…
By Nicholas Basta